{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:23:43Z","timestamp":1790421823801,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772668"],"award-info":[{"award-number":["81772668"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.clim.2019.04.006","type":"journal-article","created":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T16:28:20Z","timestamp":1555345700000},"page":"63-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Diminished cytolytic activity of \u03b3\u03b4 T cells with reduced DNAM-1 expression in neuroblastoma patients"],"prefix":"10.1016","volume":"203","author":[{"given":"Xiaolin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Mou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanmin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingang","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2019.04.006_bb0005","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.sempedsurg.2011.10.010","article-title":"The role of neoadjuvant chemotherapy in children with malignant solid tumors","volume":"21","author":"Davidoff","year":"2012","journal-title":"Semin. Pediatr. Surg."},{"key":"10.1016\/j.clim.2019.04.006_bb0010","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.4103\/0366-6999.241803","article-title":"Advances in the surgical treatment of neuroblastoma","volume":"131","author":"Luo","year":"2018","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.clim.2019.04.006_bb0015","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/jcp.25793","article-title":"GD2-targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma","volume":"233","author":"Gholamin","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.clim.2019.04.006_bb0020","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.clim.2019.04.006_bb0025","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/00002371-200009000-00004","article-title":"Human gammadelta T lymphocytes exert natural and IL-2-induced cytotoxicity to neuroblastoma cells","volume":"23","author":"Schilbach","year":"2000","journal-title":"J. Immunother."},{"key":"10.1016\/j.clim.2019.04.006_bb0030","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/14737140.2017.1285230","article-title":"Overview and recent advances in the treatment of neuroblastoma","volume":"17","author":"Whittle","year":"2017","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.clim.2019.04.006_bb0035","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nri3384","article-title":"Six-of-the-best: unique contributions of \u03b3\u03b4 T cells to immunology","volume":"13","author":"Vantourout","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.clim.2019.04.006_bb0040","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1146\/annurev.immunol.18.1.975","article-title":"[gamma][delta] cells: a right time and a right place for a conserved third way of protection","volume":"18","author":"Hayday","year":"2000","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.clim.2019.04.006_bb0045","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.4049\/jimmunol.174.3.1338","article-title":"Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma","volume":"174","author":"Viey","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2019.04.006_bb0050","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2141.2007.06754.x","article-title":"In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma","volume":"139","author":"Burjanadz\u00e9","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.clim.2019.04.006_bb0055","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/cmi.2011.28","article-title":"CDR3\u03b4 -grafted \u03b39\u03b42T cells mediate effective antitumor reactivity","volume":"9","author":"Zhao","year":"2012","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.clim.2019.04.006_bb0060","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.ejcts.2009.11.051","article-title":"A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous \u03b3\u03b4 T cells","volume":"37","author":"Nakajima","year":"2010","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.clim.2019.04.006_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049878","article-title":"Characterization of human gammadelta T lymphocytes infiltrating primary malignant melanomas","volume":"7","author":"Cordova","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.clim.2019.04.006_bb0070","first-page":"2","article-title":"Successful adoptive transfer and in vivo expansion of haploidentical \u03b3\u03b4 T cells","author":"Wilhelm","year":"2014","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.clim.2019.04.006_bb0075","doi-asserted-by":"crossref","first-page":"8900","DOI":"10.18632\/oncotarget.13051","article-title":"\u03b3\u03b4 T cells in cancer immunotherapy","volume":"8","author":"Zou","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.clim.2019.04.006_bb0080","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/CJI.0b013e318207ecfb","article-title":"Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded \u03b3\u03b4 T cells: a phase I clinical study","volume":"34","author":"Sakamoto","year":"2011","journal-title":"J. Immunother."},{"key":"10.1016\/j.clim.2019.04.006_bb0085","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1365-2249.2010.04167.x","article-title":"In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients","volume":"161","author":"Meraviglia","year":"2010","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.clim.2019.04.006_bb0090","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/CJI.0b013e3181dda207","article-title":"Bromohydrin pyrophosphate-stimulated Vgamma9delta2 T cells expanded ex vivo from patients with poor-prognosis neuroblastoma lyse autologous primary tumor cells","volume":"33","author":"Chargui","year":"2010","journal-title":"J. Immunother."},{"key":"10.1016\/j.clim.2019.04.006_bb0095","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004909","article-title":"In vivo expansion and activation of \u03b3\u03b4 T cells as immunotherapy for refractory neuroblastoma: a phase 1 study","volume":"95","author":"Pressey","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clim.2019.04.006_bb0100","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1084\/jem.20030788","article-title":"Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule","volume":"198","author":"Bottino","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2019.04.006_bb0105","doi-asserted-by":"crossref","first-page":"9180","DOI":"10.1158\/0008-5472.CAN-04-2682","article-title":"Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction","volume":"64","author":"Castriconi","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.clim.2019.04.006_bb0110","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/eji.200838409","article-title":"DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vgamma9Vdelta2 T cells","volume":"39","author":"Toutirais","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.clim.2019.04.006_bb0115","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nri3904","article-title":"\u03b3\u03b4 T cells in cancer","volume":"15","author":"Silva-Santos","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.clim.2019.04.006_bb0120","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12865-017-0216-x","article-title":"\u03b3\u03b4TFH cells promote B cell maturation and antibody production in neuroblastoma","volume":"18","author":"Mou","year":"2017","journal-title":"BMC Immunol."},{"key":"10.1016\/j.clim.2019.04.006_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2018.08.011","article-title":"A cycle involving HMGB1, IFN-\u03b3 and dendritic cells plays a putative role in anti-tumor immunity","author":"Gao","year":"2018","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.clim.2019.04.006_bb0130","first-page":"6629","article-title":"Functional characterization of VEGF- and FGF-induced tumor blood vessel models in human cancer xenografts","volume":"37","author":"Hori","year":"2017","journal-title":"Anticancer Res."},{"key":"10.1016\/j.clim.2019.04.006_bb0135","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1182\/blood-2002-07-1956","article-title":"VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression","volume":"101","author":"Ohm","year":"2003","journal-title":"Blood."},{"key":"10.1016\/j.clim.2019.04.006_bb0140","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2019.04.006_bb0145","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.clim.2019.04.006_bb0150","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fimmu.2015.00037","article-title":"The Jekyll and Hyde story of IL17-producing \u03b3\u03b4T cells","volume":"6","author":"Patil","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2019.04.006_bb0155","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1086\/605413","article-title":"Phosphoantigen-expanded human gammadelta T cells display potent cytotoxicity against monocyte-derived macrophages infected with human and avian influenza viruses","volume":"200","author":"Qin","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.clim.2019.04.006_bb0160","first-page":"10","article-title":"Lysis of aminobisphosphonate-sensitized MCF-7 breast tumor cells by V\u03b39V\u03b42 T cells","volume":"10","author":"Dhar","year":"2010","journal-title":"Cancer Immun."},{"key":"10.1016\/j.clim.2019.04.006_bb0165","doi-asserted-by":"crossref","first-page":"5954","DOI":"10.18632\/oncotarget.13979","article-title":"Low-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and \u03b3\u03b4 T cell-mediated lysis in multiple myeloma","volume":"8","author":"Niu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clim.2019.04.006_bb0170","article-title":"PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance","volume":"5","author":"Dondero","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.clim.2019.04.006_bb0175","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2781","article-title":"Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity","volume":"10","author":"Bonneville","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.clim.2019.04.006_bb0180","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.1158\/0008-5472.CAN-16-0992","article-title":"Thymic stromal chemokine TSLP acts through Th2 cytokine production to induce cutaneous T-cell lymphoma","volume":"76","author":"Takahashi","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.clim.2019.04.006_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cellimm.2015.06.001","article-title":"Introduction to cellular immunology special issue on \u03b3\u03b4 T cells","volume":"296","author":"Adams","year":"2015","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.clim.2019.04.006_bb0190","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.exphem.2009.04.008","article-title":"Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma","volume":"37","author":"Abe","year":"2009","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.clim.2019.04.006_bb0200","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/mt.2013.38","article-title":"Mechanisms of the antitumor activity of human V\u03b39V\u03b42 T cells in combination with zoledronic acid in a preclinical model of neuroblastoma","volume":"21","author":"Di Carlo","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.clim.2019.04.006_bb0205","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1158\/1078-0432.CCR-13-3464","article-title":"Neuroblastoma killing properties of V\u03b42 and V\u03b42-negative \u03b3\u03b4T cells following expansion by artificial antigen-presenting cells","volume":"20","author":"Fisher","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2019.04.006_bb0210","first-page":"114","article-title":"Glycobiology of neuroblastoma: impact on tumor behavior, prognosis, and therapeutic strategies","volume":"4","author":"Berois","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.clim.2019.04.006_bb0215","doi-asserted-by":"crossref","first-page":"14","DOI":"10.21037\/cco.2018.04.06","article-title":"Emerging role of immunotherapy for childhood cancers","volume":"7","author":"Handgretinger","year":"2018","journal-title":"Chin. Clin. Oncol."},{"key":"10.1016\/j.clim.2019.04.006_bb0220","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3109\/14653249.2012.700766","article-title":"Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells","volume":"14","author":"Knight","year":"2012","journal-title":"Cytotherapy."},{"key":"10.1016\/j.clim.2019.04.006_bb0225","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3389\/fimmu.2018.00984","article-title":"Human \u03b3\u03b4 T-cells: from surface receptors to the therapy of high-risk leukemias","volume":"9","author":"Pistoia","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2019.04.006_bb0230","doi-asserted-by":"crossref","DOI":"10.4161\/onci.26663","article-title":"Chemotherapy-elicited up-regulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma","volume":"2","author":"Soriani","year":"2013","journal-title":"Oncoimmunology."},{"key":"10.1016\/j.clim.2019.04.006_bb0235","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00262-016-1799-4","article-title":"Immunoreceptor TIGIT inhibits the cytotoxicity of human cytokine-induced killer cells by interacting with CD155","volume":"65","author":"Zhang","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.clim.2019.04.006_bb0240","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ccell.2014.11.016","article-title":"TIGIT and CD226: tipping the balance between costimulatory and coinhibitory molecules to augment the cancer immunotherapy toolkit","volume":"26","author":"Pauken","year":"2014","journal-title":"Cancer Cell"}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661618307472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661618307472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:39:02Z","timestamp":1663288742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661618307472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":47,"alternative-id":["S1521661618307472"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2019.04.006","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diminished cytolytic activity of \u03b3\u03b4 T cells with reduced DNAM-1 expression in neuroblastoma patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2019.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}